Autopsy report · NCT00317369

A Dose-finding Study of OPC-6535 in Patients With Active Crohn's Disease

“Efficacy was not cleared at US study”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 3 months before it stopped.
• 29 participants enrolled.
• Results were posted on the registry 13 years 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Otsuka Pharmaceutical Co., Ltd.

Sponsor type

Industry

Conditions

Crohn Disease

Interventions

OPC-6535(Tetomilast)

Participants

29

Sites

8

Countries

Japan

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.